A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Clinical Trial ID NCT01307267

PubWeight™ 35.08‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01307267

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
2 Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2013 1.55
3 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
4 Antibody-based immunotherapy of cancer. Cell 2012 1.35
5 Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013 1.33
6 Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012 1.26
7 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
8 The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013 1.16
9 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
10 Combination strategies to enhance antitumor ADCC. Immunotherapy 2012 1.12
11 The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol 2015 1.08
12 Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016 1.06
13 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
14 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
15 Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov 2015 0.88
16 Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer 2015 0.88
17 Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol 2015 0.85
18 Principles of antibody-mediated TNF receptor activation. Cell Death Differ 2015 0.84
19 The tumor microenvironment in esophageal cancer. Oncogene 2016 0.83
20 Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 2013 0.83
21 Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Canc Netw 2014 0.82
22 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother 2016 0.81
23 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
24 Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res 2015 0.81
25 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
26 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
27 The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016 0.80
28 Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012 0.80
29 Antibody-based immunotherapy for malignant glioma. Semin Oncol 2014 0.80
30 CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology 2014 0.79
31 Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015 0.79
32 New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res 2015 0.78
33 Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A 2015 0.77
34 Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology 2016 0.75
35 Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 2016 0.75
36 Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology 2016 0.75
37 Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncoimmunology 2015 0.75
Next 100